Targeting the evolution of drug resistance in lung cancer
Khyati Niral Shah1, Sourav Bandyopadhyay1
1Department of Bioengineering and Therapeutic Sciences, UCSF, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Abstract:
Even in their intended disease subset, Epithelial Growth Factor Receptor tyrosine kinase inhibitors leave behind residual disease eventually resulting in acquired resistance. Our study indicates that this process is driven by Aurora Kinase A. Inhibition of Aurora signaling may prevent the onset of acquired resistance and counteract progressive disease.
Insights
Epithelial Growth Factor Receptor tyrosine kinase inhibitors can lead to acquired resistance. This study shows Aurora Kinase A drives this resistance, suggesting its inhibition may prevent it.
Area of Science:
- Oncology
- Molecular Biology
- Drug Resistance
Background:
- Epithelial Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard treatments for certain cancers.
- Acquired resistance to EGFR TKIs remains a significant clinical challenge, leading to treatment failure and disease progression.
Purpose of the Study:
- To investigate the molecular mechanisms underlying acquired resistance to EGFR TKIs.
- To identify potential therapeutic targets for overcoming or preventing EGFR TKI resistance.
Main Methods:
- Analysis of residual disease in patients treated with EGFR TKIs.
- Investigating the role of Aurora Kinase A in the development of acquired resistance.
Main Results:
- The study identified Aurora Kinase A as a key driver of acquired resistance to EGFR TKIs.
- Inhibition of Aurora Kinase A signaling was shown to potentially prevent or counteract resistance.
Conclusions:
- Aurora Kinase A plays a critical role in the development of acquired resistance to EGFR TKIs.
- Targeting Aurora Kinase A signaling represents a promising strategy to overcome TKI resistance and improve patient outcomes.
Related Concept Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
11:56Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
08:03Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
04:17Dose Escalation: A Method for Developing Drug Resistance in Cancer Cells
09:00Testing the Role of Multicopy Plasmids in the Evolution of Antibiotic Resistance